

### **IN THE CLAIMS**

Please amend the claims as follows:

---

**Claims 1-86 (Cancelled)**

---

86. (Currently Amended) A therapeutic method for treating a bone-associated cancer comprising:

- (a) hydrating said cancer patient by administration of water;
- (b) parenterally administering a single dose of  $^{166}\text{Ho}$ -DOTMP to said patient in an aqueous vehicle comprising an effective antiradiolytic amount of a pharmaceutically acceptable radioprotectant, said dose being effective to deliver about 20-60 Gy to the bone marrow of said patient;
- (c) administering a dose of at least about 200 mg/m<sup>2</sup> melphalan to the patient; and
- (d) providing the patient with an autologous stem cell transplant;

wherein the patient is not subjected to total body irradiation in conjunction with the therapeutic method.

---

87. (Previously added) The method of claim 86 wherein the cancer is multiple myeloma.

88. (Previously added) The method of claim 86 wherein the cancer is metastatic breast or prostate cancer.

89. (Previously added) The method of claim 86 wherein the cancer is Ewing's sarcoma.

90. (Previously added) The method of claim 86, 87 or 88 wherein the radioprotectant is ascorbic acid or gentisic acid.

91. (Previously added) The method of claim 90 wherein the concentration of ascorbic acid is about 35-75 mg/ml.

92. (Previously added) The method of claim 91 wherein the vehicle is buffered to about pH 7-8.

*b2*  
93. (Currently amended) The method of claim 90 or 92 wherein the dose is effective to deliver about 20-30 Gy to the bone marrow of said patient.

Claims 94 – 99 (cancelled).

100. (Previously added) A liquid pharmaceutical composition comprising  $^{166}\text{Ho}$  complexed with 1,4,7,10-tetraazacyclododecanetetramethylene-phosphonic acid (DOTMP) and an effective antiradiolytic amount of a pharmaceutically acceptable radioprotectant.

101. (Previously added) The composition of claim 100, wherein the radioprotectant is ascorbic acid or gentisic acid.

102. (Previously added) The composition of claim 101 comprising about 35-75 mg ascorbic acid/ml of composition.

103. (Previously added) The composition of claim 100 or 101 wherein the ratio of DOTMP to  $^{166}\text{Ho}$  is above 3.

104. (Previously added) The composition of claim 100, comprising an aqueous carrier adjusted to pH 7-8.

105. (Previously added) The composition of claim 100 which is stable for at least 72 hours under ambient conditions.